drugset
drugset / Trial / NCT04494815

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

NCT04494815 ↗

Phase 1/2 Completed 24 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

This study is to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients with Peripheral Neuropathic Pain

Timeline

Start
2020-09-18
Primary completion
2022-05-31
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SR419 Unknown 20 mg Oral

Indications

neuropathy, painful